Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline

Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline

Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the company's pipeline, looking for the next drug that will drive future growth. Fortunately, Vertex has a combination under review by U.S. and EU regulators, and is preparing to test a pair of triple combinations that the company thinks will allow it to treat 90% of cystic fibrosis patients.

Metric

Q3 2017

Continue reading

Source: Fool.com